New combo aims to boost lung cancer treatment

NCT ID NCT06644768

Ongoing Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This study tests whether adding valemetostat to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has high PD-L1 levels. About 137 adults who have not had prior treatment will participate. The goal is to see if the combination can delay cancer growth and improve response rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: valemetostat tosylate and pembrolizumab
What this could lead to: If successful, this combination could offer a new first-line treatment option for people with advanced lung cancer that has high PD-L1 levels.
What could go wrong: This is an early-phase trial (1b/2) with only 137 participants, so results may not confirm benefit. Adding valemetostat may increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

BRCR Global

Plantation, Florida, 33322-5426, United States
CINPAM Centro Integrado De Pesquisa Da Amazonia

Manaus, 69005-080, Brazil
California Research Institute

Los Angeles, California, 90027, United States
Cancer Institute Hospital of JFCR

Kōtoku, 135-8550, Japan
Centro de Pesquisas Clinica Reichow

Blumenau, 89010-340, Brazil
Clinica Viedma S.A.

Viedma, R8500ACE, Argentina
Clínica de Neoplasias Litoral Ltda.

ItajaĂ-, 88301-220, Brazil
Columbia University Irving Medical Center

New York, New York, 10032, United States
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto

Sao Jose Rio Preto, 15090-000, Brazil
Fundacion Ars Medica

N Salvador de Jujuy, 4600, Argentina
Harbin Medical University Cancer Hospital

Harbin, 150081, China
Henan Cancer Hospital

Zhengzhou, 450003, China
Hospital Italiano de Buenos Aires

Buenos Aires, 1199, Argentina
Hospital Nossa Senhora da Conceicao

Porto Alegre, 91350-280, Brazil
Instituto Alexander Fleming

Buenos Aires, 1426, Argentina
Instituto Medico de La Fundacion Estudios Clinicos

Rosario, 2000, Argentina
Jiamusi Cancer Hospital

Jiamusi, 154007, China
Jilin Cancer Hospital

Changchun, 130000, China
Kitasato University Hospital

Sagamihara-shi, 252-0375, Japan
Kyushu University Hospital

Fukuoka, 812-8582, Japan
Liga Norte-Rio-Grandense Contra o Câncer

Natal, 59062-000, Brazil
Mayo Clinic - Rochester

Rochester, Minnesota, 55904, United States
Mayo Clinic Hospital

Jacksonville, Florida, 32224, United States
NHO Nagoya Medical Center

Nagoya, 460-0001, Japan
National Cancer Center Hospital East

Kashiwa, 277-8577, Japan
Pikeville Medical Center

Pikeville, Kentucky, 41501, United States
Sanatorio Allende

Córdoba, X5000JHQ, Argentina
Shanghai East Hospital

Shanghai, 200120, China
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine

Hangzhou, 242332, China
Thomas Jefferson University, Sidney Kimmel Cancer Center

Philadelphia, Pennsylvania, 19107, United States
Tianjin Medical University Cancer Institute & Hospital

Tiyuan, 300060, China
University of California San Diego (Ucsd)-Moores Cancer Center

La Jolla, California, 92037, United States
University of Kentucky Medical Center

Lexington, Kentucky, 40536, United States
Valkyrie Clinical Trials

Los Angeles, California, 90067, United States
Virginia Cancer Specialist

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.